Atrial Fibrillation, Cognitive Decline, and Dementia: an Epidemiologic Review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.
Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042–6.
Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J. 2006;27:949–53.
Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial ribrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–5.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.
Piccini JP, Hammill BG, Sinner MF, Hernandez AF, Walkey AJ, Benjamin EJ, et al. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. Eur Heart J. 2014;35:250–6.
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–47.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.
Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12:267–77.
Alzheimer’s Disease International. World Alzheimer report 2015. London: Alzheimer’s Disease International; 2015.
Wortmann M. Dementia: a global health priority—highlights from an ADI and World Health Organization report. Alzheimers Res Ther. 2012;4:40.
Alzheimer’s Disease International (ADI). Policy brief for G8 heads of government. The global impact of dementia 2013–2050. London: ADI; 2013.
•• Dagres N, Chao T-F, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace 2018. doi: https://doi.org/10.1093/europace/euy046 . A comprehensive expert consensus on arrhtymia and cognitive function with detailed literature review on the impact of different types of arrhythmias on cognitive function, as well as implications for furtuer research and clinical practice regarding prevention and treatment strategies.
Nishtala A, Piers RJ, Himali JJ, Beiser AS, Davis-Plourde KL, Saczynski JS, et al. Atrial fibrillation and cognitive decline in the Framingham Heart Study. Hear Rhythm. 2018;15:166–72.
•• Chen LY, Norby FL, Gottesman RF, Mosley TH, Soliman EZ, Agarwal SK, et al. Association of atrial fibrillation with cognitive decline and dementia over 20 years: the ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study). J Am Heart Assoc. 2018;7:e007301. A large longitudinal population-based study showed that AF is associated with greater cognitive decline and higher risk of dementia, independent of ischemic stroke.
•• Singh-Manoux A, Fayosse A, Sabia S, Canonico M, Bobak M, Elbaz A, et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. Eur Heart J 2017;38:2612–2618. A large longitudinal population-based study that showed that longer exposure to AF was associated with faster cognitive decline, independent of incident stroke.
•• de Bruijn RF, Heeringa J, Wolters FJ, Franco OH, Stricker BHC, Hofman A, et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 2015;72:1288–94. A large longitudinal population-based study that demonstrated a higher dementia risk associated with AF only among participants younger than 67 years
Rusanen M, Kivipelto M, Levälahti E, Laatikainen T, Tuomilehto J, Soininen H, et al. Heart diseases and long-term risk of dementia and Alzheimer’s disease: a population-based CAIDE study. J Alzheimers Dis. 2014;42:183–91.
Thacker EL, McKnight B, Psaty BM, Longstreth WT, Sitlani CM, Dublin S, et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology. 2013;81:119–25.
Haring B, Leng X, Robinson J, Johnson KC, Jackson RD, Beyth R, et al. Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women’s Health Initiative Memory Study. J Am Heart Assoc. 2013;2:e000369.
Marzona I, O’Donnell M, Teo K, Gao P, Anderson C, Bosch J, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. Can Med Assoc J. 2012;184:e329–36.
Dublin S, Anderson ML, Haneuse SJ, Heckbert SR, Crane PK, Breitner JCS, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc. 2011;59:1369–75.
Marengoni A, Qiu C, Winblad B, Fratiglioni L. Atrial fibrillation, stroke and dementia in the very old: a population-based study. Neurobiol Aging. 2011;32:1336–7.
Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Hear Rhythm. 2010;7:433–7.
Peters R, Poulter R, Beckett N, Forette F, Fagard R, Potter J, et al. Cardiovascular and biochemical risk factors for incident dementia in the hypertension in the very elderly trial. J Hypertens. 2009;27:2055–62.
Rastas S, Verkkoniemi A, Polvikoski T, Juva K, Niinistö L, Mattila K, et al. Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. Stroke. 2007;38:1454–60.
Tilvis RS, Kähönen-Väre MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci. 2004;59:268–74.
• Proietti M, Recchia A, Riva E, Lucca U, Tettamanti M, Mannucci PM, et al. Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. Eur J Intern Med. 2017;46:6–10. The first review that solely focused on the association between AF and dementia in very old people (≥ 80 years) and found no reliable evidence supporting an association between AF and increased risk of dementia in the very old.
Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76:914–22.
Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda Brantes M, et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. Hear Rhythm. 2012;9:1761–8.
Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation. Ann Intern Med. 2013;158:338–46.
Dietzel J, Haeusler KG, Endres M. Does atrial fibrillation cause cognitive decline and dementia? Europace. 2018;20:408–19.
Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. Circulation. 2017;136:583–96.
Aldrugh S, Sardana M, Henninger N, Saczynski JS, McManus DD. Atrial fibrillation, cognition and dementia: a review. J Cardiovasc Electrophysiol. 2017;28:958–65.
Rivard L, Khairy P. Mechanisms, clinical significance, and prevention of cognitive impairment in patients with atrial fibrillation. Can J Cardiol. 2017;33:1556–64.
Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol. 2009;118:103–13.
DeSimone CV, Graff-Radford J, El-Harasis MA, Rabinstein AA, Asirvatham SJ, Holmes DR. Cerebral amyloid angiopathy. J Am Coll Cardiol. 2017;70:1173–82.
Ihara M, Washida K. Linking atrial fibrillation with Alzheimer’s disease: epidemiological, pathological, and mechanistic evidence. J Alzheimers Dis. 2018;62:61–72.
Alosco ML, Spitznagel MB, Sweet LH, Josephson R, Hughes J, Gunstad J. Atrial fibrillation exacerbates cognitive dysfunction and cerebral perfusion in heart failure. Pacing Clin Electrophysiol. 2015;38:178–86.
Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263–70.
Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation. J Am Coll Cardiol. 2007;50:2021–8.
Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med. 2011;17:556–63.
Hu Y-F, Chen Y-J, Lin Y-J, Chen S-A. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12:230–43.
Takeda S, Sato N, Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci. 2014;6:171.
Wersching H, Duning T, Lohmann H, Mohammadi S, Stehling C, Fobker M, et al. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology. 2010;74:1022–9.
Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52:168–74.
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689–701.
Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. Stroke Vasc Neurol. 2016;1:83–92.
Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–38.
Ding J, Sigurðsson S, Jónsson PV, Eiriksdottir G, Charidimou A, Lopez OL, et al. Large perivascular spaces visible on magnetic resonance imaging, cerebral small vessel disease progression, and risk of dementia: the Age, Gene/Environment Susceptibility-Reykjavik Study. JAMA Neurol. 2017;74:1105–12.
Kalantarian S, Ay H, Gollub RL, Lee H, Retzepi K, Mansour M, et al. Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. Ann Intern Med. 2014;161:650–8.
Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MMB, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34:1126–9.
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215–22.
Chen LY, Lopez FL, Gottesman RF, Huxley RR, Agarwal SK, Loehr L, et al. Atrial fibrillation and cognitive decline-the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. Stroke. 2014;45:2568–74.
• Mayasi Y, Helenius J, McManus DD, Goddeau RP, Jun-O’Connell AH, Moonis M, et al. Atrial fibrillation is associated with anterior predominant white matter lesions in patients presenting with embolic stroke. J Neurol Neurosurg Psychiatry. 2018;89:6–13. A small register-based study that showed that AF was associated with anterior subcortical white matter hyperintensity, which suggests that the link between AF and brain injuries goes beyond thromboembolic mechanisms.
Kobayashi A, Iguchi M, Shimizu S, Uchiyama S. Silent cerebral infarcts and cerebral white matter lesions in patients with nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis. 2012;21:310–7.
Piers RJ, Nishtala A, Preis SR, DeCarli C, Wolf PA, Benjamin EJ, et al. Association between atrial fibrillation and volumetric magnetic resonance imaging brain measures: Framingham Offspring Study. Hear Rhythm. 2016;13:2020–4.
Goldberg I, Auriel E, Russell D, Korczyn AD. Microembolism, silent brain infarcts and dementia. J Neurol Sci. 2012;322:250–3.
Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666.
Thong JYJ, Hilal S, Wang Y, Soon HW, Dong Y, Collinson SL, et al. Association of silent lacunar infarct with brain atrophy and cognitive impairment. J Neurol Neurosurg Psychiatry. 2013;84:1219–25.
Payabvash S, Souza LCS, Wang Y, Schaefer PW, Furie KL, Halpern EF, et al. Regional ischemic vulnerability of the brain to hypoperfusion: the need for location specific computed tomography perfusion thresholds in acute stroke patients. Stroke. 2011;42:1255–60.
Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front Neurol. 2014;4:205.
Knecht S, Oelschläger C, Duning T, Lohmann H, Albers J, Stehling C, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29:2125–32.
Stefansdottir H, Arnar DO, Aspelund T, Sigurdsson S, Jonsdottir MK, Hjaltason H, et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke. 2013;44:1020–5.
Saito T, Kawamura Y, Tanabe Y, Asanome A, Takahashi K, Sawada J, et al. Cerebral microbleeds and asymptomatic cerebral infarctions in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2014;23:1616–22.
Diener H-C, Selim MH, Molina CA, Greenberg SM. Embolic stroke, atrial fibrillation, and microbleeds. Stroke. 2016;47:904–7.
Song T-J, Kim J, Lee HS, Nam CM, Nam HS, Heo JH, et al. The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fibrillation. Eur J Neurol. 2013;20:502–8.
Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der Lugt A, Hofman A, et al. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol. 2016;73:934–43.
Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.
Jacobs V, Cutler MJ, Day JD, Bunch TJ. Atrial fibrillation and dementia. Trends Cardiovasc Med. 2015;25:44–51.
Hui DS, Morley JE, Mikolajczak PC, Lee R. Atrial fibrillation: a major risk factor for cognitive decline. Am Heart J. 2015;169:448–56.
Poggesi A, Inzitari D, Pantoni L. Atrial fibrillation and cognition: epidemiological data and possible mechanisms. Stroke. 2015;46:3316–21.
Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH, et al. “Real-world” antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey. Am J Med. 2014;127:519–529.e1.
• Moffitt P, Lane DA, Park H, O’Connell J, Quinn TJ. Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. Age Ageing 2016;45:767–75. A meta-analysis that explored the cognitive effect of AF thromboprophylaxis and showed no definitive evidence of protective or harmful effect of anticoagulant drugs on cognitive function in AF patients.
•• Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J. 2018;39:453–60. A large retrospective register-based study that showed that the risk of dementia was 29% lower in AF patients on anticoagulant treatment than those who did not use anticoagulant drugs.
• Madhavan M, Hu TY, Gersh BJ, Roger VL, Killian J, Weston SA, Graff-Radford J, Asirvatham SJ, Chamberlain AM Efficacy of warfarin anticoagulation and incident dementia in a community-based cohort of atrial fibrillation. Mayo Clin Proc 2018;93:145–54. A community-based study that demonstrated that warfarin therapy was associated with 20% reduction in the risk of dementia in patients with AF.
• Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol 2016;118:210–4. A community-based study that showed that use of noval oral anticoagulant drugs was associated with a reduced risk of cerebral ischemic events and new-onset dementia compared to warfarin.
Cheng W, Liu W, Li B, Li D. Relationship of anticoagulant therapy with cognitive impairment among patients with atrial fibrillation. J Cardiovasc Pharmacol. 2018;71:380–7.
Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:277–83.
Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Hear Rhythm. 2014;11:2206–13.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796–801.
Lip GYH. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol. 2011;8:602–6.
Veronese N, Stubbs B, Maggi S, Thompson T, Schofield P, Muller C, et al. Low-dose aspirin use and cognitive function in older age: a systematic review and meta-analysis. J Am Geriatr Soc. 2017;65:1763–8.
Albert MA, Danielson E, Rifai N, Ridker PM. For the PRINCE investigators. Effect of statin therapy on C-reactive protein levels. JAMA. 2001;286:64–70.
• Chao T-F, Liu C-J, Chen S-J, Wang K-L, \, Chang S-L, et al. Statins and the risk of dementia in patients with atrial fibrillation: a nationwide population-based cohort study. Int J Cardiol 2015;196:91–97. A large register-based study that showed that use of statin was associated with lower risk of non-vascular dementia.
Lappegård KT, Pop-Purceleanu M, van Heerde W, Sexton J, Tendolkar I, Pop G. Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy. J Neuroinflammation. 2013;10:844.
Chung MK, Shemanski L, Sherman DG, Greene HL, Hogan DB, Kellen JC, et al. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol. 2005;46:1891–9.